Ahmedabad-based Cadila Pharmaceuticals has announced the launch of Cadiflu  Tetra  Vaccine,  an  advanced  Quadrivalent Influenza Vaccine to prevent influenza, a recurrent, widespread and debilitating viral infection. The vaccine is approved by Drugs Controller General of India (DCGI) for use in adults and children.

Cadiflu  Tetra  Vaccine  targets  four  strains  of  the  Influenza  virus  subtype–A  and  B,  responsible  for seasonal  epidemics.  Developed  using  cutting-edge  proprietary  technology  employing  nano-sized particles, the  vaccine mimics  the  external  structure  of  the  virus  without  containing  intact  genetic material.

The  vaccine carries hemagglutinin (HA), neuraminidase (NA) and matrix  1  (M1)  proteins  from  the respective  strains  aggregated  together in a single  formulation.  The  VLP  vaccine  replicates  external structure of the viruses but does not contain any live genetic substance, which can cause viral replication and infection. Therefore, this vaccine is qualitatively superior and has better safety profile. 

The Cadiflu Tetra Vaccine aims to reduce the incidence of influenza illness, mitigate the severity of the disease  in  affected  individuals,  and  decrease  the  transmission  of  the  infection  to  others.  This breakthrough  in  vaccine  development  also  holds  promise  for  enhancing  the  protection  of  pregnant women against influenza, contributing to the overall well-being of both mother and child.